AC Immune SA
(NASDAQ : ACIU)

( )
ACIU PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 0.14%171.450.7%$971.15m
ABBVAbbVie, Inc. 0.24%138.401.9%$830.15m
PFEPfizer Inc. 0.08%49.290.9%$825.43m
LLYEli Lilly & Co. 0.04%301.441.1%$746.49m
MRKMerck & Co., Inc. 0.25%87.420.7%$739.97m
BMYBristol-Myers Squibb Co. 0.21%72.271.0%$651.18m
SIGASIGA Technologies, Inc. 1.50%23.650.0%$419.06m
AZNAstraZeneca Plc -0.58%65.651.0%$379.27m
ALNYAlnylam Pharmaceuticals, Inc. 0.00%218.588.1%$241.27m
GSKGSK Plc 0.12%40.620.3%$218.13m
HZNPHorizon Therapeutics Plc 0.00%69.605.4%$197.79m
SGENSeagen Inc. -0.46%175.005.7%$187.87m
NVSNovartis AG 0.49%85.990.2%$174.24m
RGENRepligen Corp. 0.00%246.276.7%$155.75m
NVONovo Nordisk A/S -0.56%102.640.1%$152.07m

Company Profile

AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.